827 related articles for article (PubMed ID: 27793053)
21. EZH2-Mediated H3K27me3 Is Involved in Epigenetic Repression of Deleted in Liver Cancer 1 in Human Cancers.
Au SL; Wong CC; Lee JM; Wong CM; Ng IO
PLoS One; 2013; 8(6):e68226. PubMed ID: 23826380
[TBL] [Abstract][Full Text] [Related]
22. A Novel Role of Silibinin as a Putative Epigenetic Modulator in Human Prostate Carcinoma.
Anestopoulos I; Sfakianos AP; Franco R; Chlichlia K; Panayiotidis MI; Kroll DJ; Pappa A
Molecules; 2016 Dec; 22(1):. PubMed ID: 28042859
[TBL] [Abstract][Full Text] [Related]
23. EZH2 mutations and promoter hypermethylation in childhood acute lymphoblastic leukemia.
Schäfer V; Ernst J; Rinke J; Winkelmann N; Beck JF; Hochhaus A; Gruhn B; Ernst T
J Cancer Res Clin Oncol; 2016 Jul; 142(7):1641-50. PubMed ID: 27169594
[TBL] [Abstract][Full Text] [Related]
24. Role of EZH2 in cancer stem cells: from biological insight to a therapeutic target.
Wen Y; Cai J; Hou Y; Huang Z; Wang Z
Oncotarget; 2017 Jun; 8(23):37974-37990. PubMed ID: 28415635
[TBL] [Abstract][Full Text] [Related]
25. Epigenetic regulation of enhancer of zeste homolog 2 (EZH2) -Yin Yang 1 (YY1) axis in cancer.
Chandnani N; Gupta I; Thakkar V; Sarkar K
Pathol Res Pract; 2023 Nov; 251():154885. PubMed ID: 37862922
[TBL] [Abstract][Full Text] [Related]
26. EZH2-mediated Puma gene repression regulates non-small cell lung cancer cell proliferation and cisplatin-induced apoptosis.
Liu H; Li W; Yu X; Gao F; Duan Z; Ma X; Tan S; Yuan Y; Liu L; Wang J; Zhou X; Yang Y
Oncotarget; 2016 Aug; 7(35):56338-56354. PubMed ID: 27472460
[TBL] [Abstract][Full Text] [Related]
27. The role of EZH1 and EZH2 in development and cancer.
Lee SH; Li Y; Kim H; Eum S; Park K; Lee CH
BMB Rep; 2022 Dec; 55(12):595-601. PubMed ID: 36476271
[TBL] [Abstract][Full Text] [Related]
28. EZH2-mediated repression of GSK-3β and TP53 promotes Wnt/β-catenin signaling-dependent cell expansion in cervical carcinoma.
Chen Q; Zheng PS; Yang WT
Oncotarget; 2016 Jun; 7(24):36115-36129. PubMed ID: 27092879
[TBL] [Abstract][Full Text] [Related]
29. Histone Methyltransferase EZH2: A Therapeutic Target for Ovarian Cancer.
Jones BA; Varambally S; Arend RC
Mol Cancer Ther; 2018 Mar; 17(3):591-602. PubMed ID: 29726819
[TBL] [Abstract][Full Text] [Related]
30. BRCA1 and EZH2 cooperate in regulation of prostate cancer stem cell phenotype.
Gorodetska I; Lukiyanchuk V; Peitzsch C; Kozeretska I; Dubrovska A
Int J Cancer; 2019 Dec; 145(11):2974-2985. PubMed ID: 30968962
[TBL] [Abstract][Full Text] [Related]
31. Astemizole arrests the proliferation of cancer cells by disrupting the EZH2-EED interaction of polycomb repressive complex 2.
Kong X; Chen L; Jiao L; Jiang X; Lian F; Lu J; Zhu K; Du D; Liu J; Ding H; Zhang N; Shen J; Zheng M; Chen K; Liu X; Jiang H; Luo C
J Med Chem; 2014 Nov; 57(22):9512-21. PubMed ID: 25369470
[TBL] [Abstract][Full Text] [Related]
32. EZH2 inhibition in multiple myeloma downregulates myeloma associated oncogenes and upregulates microRNAs with potential tumor suppressor functions.
Alzrigat M; Párraga AA; Agarwal P; Zureigat H; Österborg A; Nahi H; Ma A; Jin J; Nilsson K; Öberg F; Kalushkova A; Jernberg-Wiklund H
Oncotarget; 2017 Feb; 8(6):10213-10224. PubMed ID: 28052011
[TBL] [Abstract][Full Text] [Related]
33. [EZH2 is therapeutic target for personalized treatment in multiple myeloma].
Herviou L; Cavalli G; Moreaux J
Bull Cancer; 2018 Sep; 105(9):804-819. PubMed ID: 30041976
[TBL] [Abstract][Full Text] [Related]
34. Dissecting the role of H3K27 acetylation and methylation in PRC2 mediated control of cellular identity.
Lavarone E; Barbieri CM; Pasini D
Nat Commun; 2019 Apr; 10(1):1679. PubMed ID: 30976011
[TBL] [Abstract][Full Text] [Related]
35. Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.
Sigalotti L; Fratta E; Coral S; Cortini E; Covre A; Nicolay HJ; Anzalone L; Pezzani L; Di Giacomo AM; Fonsatti E; Colizzi F; Altomonte M; Calabrò L; Maio M
J Cell Physiol; 2007 Aug; 212(2):330-44. PubMed ID: 17458893
[TBL] [Abstract][Full Text] [Related]
36. EZH2 in Cancer Progression and Potential Application in Cancer Therapy: A Friend or Foe?
Yan KS; Lin CY; Liao TW; Peng CM; Lee SC; Liu YJ; Chan WP; Chou RH
Int J Mol Sci; 2017 May; 18(6):. PubMed ID: 28561778
[TBL] [Abstract][Full Text] [Related]
37. The polycomb group gene product Ezh2 regulates proliferation and differentiation of murine hepatic stem/progenitor cells.
Aoki R; Chiba T; Miyagi S; Negishi M; Konuma T; Taniguchi H; Ogawa M; Yokosuka O; Iwama A
J Hepatol; 2010 Jun; 52(6):854-63. PubMed ID: 20395008
[TBL] [Abstract][Full Text] [Related]
38. Functional and therapeutic significance of EZH2 in urological cancers.
Liu X; Wu Q; Li L
Oncotarget; 2017 Jun; 8(23):38044-38055. PubMed ID: 28410242
[TBL] [Abstract][Full Text] [Related]
39. Preclinical Evidence of Anti-Tumor Activity Induced by EZH2 Inhibition in Human Models of Synovial Sarcoma.
Kawano S; Grassian AR; Tsuda M; Knutson SK; Warholic NM; Kuznetsov G; Xu S; Xiao Y; Pollock RM; Smith JS; Kuntz KK; Ribich S; Minoshima Y; Matsui J; Copeland RA; Tanaka S; Keilhack H
PLoS One; 2016; 11(7):e0158888. PubMed ID: 27391784
[TBL] [Abstract][Full Text] [Related]
40. Polycomb repressive complex 2 and its core component EZH2: potential targeted therapeutic strategies for head and neck squamous cell carcinoma.
Cheng Y; Song Z; Fang X; Tang Z
Clin Epigenetics; 2024 Apr; 16(1):54. PubMed ID: 38600608
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
